This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herr, H. W. Search for Related Content PubMed PubMed Citation Articles by Herr, H. W. Social Bookmarking                            What's this?

Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year Outcome

From the Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Harry W. Herr, MD, 1275 York Ave, New York, NY 10021; email herrh{at}mskcc.org

PURPOSE: To determine the 10-year outcome of patients with muscle-invasive bladder cancer treated by transurethral resection (TUR) alone.

PATIENTS AND METHODS: Of 432 newly evaluated patients with muscle-invasive bladder cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TUR of the primary tumor site showed no (T0) or only non–muscle-invasive (T1) residual tumor. Patients were followed-up every 3 to 6 months thereafter for a minimum of 10 years and up to 20 years. Primary end points of the study were disease-specific survival, survival with a bladder, frequency of recurrent invasive tumors in the bladder, and survival after salvage cystectomy.

RESULTS: The 10-year disease-specific survival was 76% of 99 patients who received TUR as definitive therapy (57% with bladder preserved) compared with 71% of 52 patients who had immediate cystectomy (P = .3). Of the 99 patients treated with TUR, 82% of 73 who had T0 on restaging TUR survived versus 57% of the 26 patients who had residual T1 tumor on restaging TUR (P = .003). Thirty-four patients (34%) relapsed in the bladder with a new muscle-invasive tumor, 18 (53%) were successfully treated with salvage therapy via cystectomy, and 16 patients (16%) died of disease.

CONCLUSION: Radical TUR for muscle-invasive bladder cancer is a successful bladder-sparing therapeutic strategy in selected patients who have no residual tumor on a repeat vigorous resection of the primary tumor site.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Bellmunt, S. Albiol, V. Kataja, and On behalf of the ESMO Guidelines Working Group Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv79 - iv80. [Full Text] [PDF]

				T. Tsukamoto, H. Kitamura, A. Takahashi, and N. Masumori Treatment of Invasive Bladder Cancer: Lessons from the Past and Perspective for the Future Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 295 - 306. [Abstract] [Full Text] [PDF]

				S. Madersbacher, W. Hochreiter, F. Burkhard, G. N. Thalmann, H. Danuser, R. Markwalder, and U. E. Studer Radical Cystectomy for Bladder Cancer Today--A Homogeneous Series Without Neoadjuvant Therapy J. Clin. Oncol., February 15, 2003; 21(4): 690 - 696. [Abstract] [Full Text] [PDF]

				C. Rodel, G. G. Grabenbauer, R. Kuhn, T. Papadopoulos, J. Dunst, M. Meyer, K. M. Schrott, and R. Sauer Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results J. Clin. Oncol., July 15, 2002; 20(14): 3061 - 3071. [Abstract] [Full Text] [PDF]